What Леналидомид-натив Treats — Main Uses and Benefits

Леналидомид-натив is used for managing certain cancers and serious conditions affecting blood cells and bone marrow, including multiple myeloma and various lymphomas. The medication is applicable in clinical settings involving conditions characterized by periods of heightened symptoms associated with Multiple Myeloma, specific Myelodysplastic Syndromes (MDS) with the Deletion 5q abnormality, and certain lymphomas including Mantle Cell and Follicular types. This medication supports the goals of long-term disease management, which assists in achieving and sustaining remission, thereby helping maintain the stability of the disease.

The drug is often used during phases when symptoms become more noticeable, such as for the chronic, severe anemia and profound fatigue common in MDS. Its application contributes to improved day-to-day comfort and stability, supporting functional stability. The medication is commonly used as a component of combination regimens and as maintenance therapy following intensive procedures like stem cell transplantation.

---

Quick Fact: Relief for Transfusion Burden This medication may assist in reducing the frequency of the need for red blood cell transfusions in patients with specific MDS, a key functional benefit that addresses symptoms related to physical discomfort caused by severe anemia.

Eligibility Map: Who can and cannot use Lenalidomide

Lenalidomide is strictly contraindicated in pregnant women due to the risk of severe, life-threatening birth defects (embryo-fetal toxicity). The medicine is only available through a mandatory restricted distribution program (REMS/PPP), and eligibility for all patients is contingent upon compliance with this program.

Contraindicated Populations	Use-Not-Established / Restricted
Pregnant Females: Absolute prohibition.	Paediatric Patients (Under 18): Use is not recommended as safety and effectiveness are not established.
Females of Childbearing Potential (FOCP) not complying with the mandatory Pregnancy Prevention Programme (PPP), including negative pregnancy tests and use of two reliable forms of contraception.	Patients with Severe Renal Impairment (CrCl < 30 mL/min): Requires specific dose adjustment, and caution is advised.
Patients with Known Hypersensitivity (e.g., severe allergic reaction, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide or excipients.	Patients with Chronic Lymphocytic Leukemia (CLL): Use is not recommended outside of controlled clinical trials due to increased mortality risk.

Pregnancy and Lactation Status: The medicine is contraindicated during pregnancy and breastfeeding is not recommended. Male patients must also use a barrier method of contraception during and for a specified period after treatment because the medicine is present in semen.

Interactions with other medicines and products

Official regulatory documents describe specific interaction patterns for lenalidomide, the active ingredient in Леналидомид-натив, focusing on pharmacodynamic risk, transporter-mediated exposure, and substance restrictions.

---

Pharmacodynamic and Exposure-Altering Interactions

Co-administration with certain agents is documented to increase specific risks or alter plasma concentrations:

• Erythropoietin Stimulating Agents (ESAs) and Estrogen-Containing Therapies: Combination use is associated with a formally documented increased risk of venous thromboembolic events (VTE).
• Digoxin: Lenalidomide affects the P-glycoprotein (P-gp) transporter, leading to a documented increase in Digoxin plasma levels (Cmax and AUC). Regulatory information states that periodic monitoring of Digoxin levels is required during co-administration.

---

Official Restrictions and Population Considerations

Specific restrictions and population-dependent interaction notes are documented in official prescribing information:

• Live Viral Vaccines: Due to lenalidomide’s immunomodulating effects, the use of Live Viral Vaccines is restricted or generally avoided, as this may reduce vaccine effectiveness and increase the risk of infection.
• Food and Alcohol: Lenalidomide may be taken with or without food, indicating no clinically significant food-related interaction. Smoking/Tobacco Use is officially noted as a risk factor that may increase the risk of thromboembolism.
• Renal Impairment: Kidney dysfunction reduces Lenalidomide's clearance from the body. This is formally documented as a population-specific note that leads to increased systemic drug exposure.

The mechanism of Леналидомид-натив involves targeted protein degradation and immune system modulation. The molecule engages mechanisms that modulate cell growth and immune processes.

Molecular Glue: Targeted Protein Destruction

This mechanism involves the drug binding to the Cereblon (CRBN) E3 ubiquitin ligase complex, modifying its substrate specificity. Acting as a molecular glue, the drug forces this cellular enzyme to recognize and rapidly destroy specific transcription factors, primarily Ikaros (IKZF1) and Aiolos (IKZF3). The subsequent loss of these factors initiates a cascade that results in programmed cell death and inhibition of proliferation in the target cell population.

Immunomodulation and Microenvironmental Control

The drug modulates immune system function and affects the environment of the target cells. It enhances the function and cytotoxicity of key immune cells, specifically T-lymphocytes and Natural Killer (NK) cells. Furthermore, the drug limits the production of growth-supportive factors, such as VEGF (which regulates blood vessel formation) and pro-inflammatory mediators like IL-6. This collective action modifies the microenvironment and affects the physiological state of the target cell population.

Lenalidomide-nativ is administered exclusively via the oral route and is supplied in capsule form across several strengths, including 5 mg, 10 mg, and 25 mg. The medicine is taken once daily, with the precise milligram amount determined by the specific condition being addressed, such as Multiple Myeloma or Myelodysplastic Syndromes. Its use is structured around repeated 28-day treatment cycles.

In many regimens, Lenalidomide is taken on an intermittent schedule, such as days 1 through 21 of each cycle, followed by a period off. Other usage patterns, including maintenance therapy for Multiple Myeloma or treatment for Myelodysplastic Syndromes, often follow a continuous daily schedule throughout the 28-day cycle.

For proper administration, the capsule must be swallowed whole with water and must not be opened, crushed, or chewed. It may be taken with or without food, but administration should occur at approximately the same time each day to maintain consistency. If a daily dose is missed, the protocol involves skipping the dose if the lapse is more than 12 hours from the scheduled time and resuming the normal cycle.

A critical requirement of the administration protocol is the initial dose adjustment for patients with impaired renal function. A reduced starting dose is utilized based on creatinine clearance measurements, including instructions for patients receiving dialysis.

---

Research Evidence: Overview of Studies for Леналидомид-натив (Lenalidomide)

This section describes the structure of the research that has been studied for the specific use of the drug in certain blood cancers and related conditions, focusing only on the type of studies conducted and the outcomes they monitored.

---

Evidence for Use in Multiple Myeloma

The research base for Multiple Myeloma (MM) includes a substantial number of large, international Randomized Controlled Trials (RCTs). These studies typically compare treatment against a standard approach or placebo. Trials have been conducted in adults with MM that is newly diagnosed and in cases where the disease has returned or worsened after initial treatment (relapsed or refractory MM).

Researchers studied several key time-based outcomes. The main focus was on monitoring Overall Survival (OS) and the length of time patients lived without the disease progressing (Progression-Free Survival, or PFS). Trials also monitored response rates, which describe the extent to which the disease could be measured as reduced or stable during the study period. Studies monitored and reported patterns related to survival and response in groups receiving the treatment compared to control groups. Studies contribute to the broader evidence landscape related to these long-term metrics.

---

Evidence for Use in Myelodysplastic Syndromes (MDS)

For Myelodysplastic Syndromes (MDS), the research has focused mainly on a specific patient subgroup: adults with lower-risk MDS who have a particular genetic abnormality called the chromosome 5q deletion (del(5q)). Studies included both controlled trials and longer-term observational reports.

The main outcomes monitored in these trials were outcomes related to systemic or functional imbalance, primarily monitoring the patients' need for blood transfusions. Researchers monitored whether patients achieved Red Blood Cell Transfusion Independence over defined time intervals. Research also monitored for changes in the specific genetic marker del(5q) and cellular markers.

---

️ Evidence for Use in Lymphomas (Mantle Cell and Follicular)

The research for other blood cancers, specifically Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL), includes Phase II and Phase III trials. These studies primarily monitored findings when the medicine was studied in patients whose disease had returned or resisted other treatments (relapsed or refractory setting). For Follicular Lymphoma, the research often examined outcomes when the medicine was used as part of a combination regimen with another agent.

---

What Remains Uncertain in the Research Landscape

While the research base for this drug is substantial, there are still areas where more information is needed. Evidence quality varies across studies, and some key limitations exist. For example, older trials may be less relevant to modern practice because comparative evidence is lacking against the newest emerging therapies. Additionally, there is limited information for long-term outcomes on the best way to sequence treatment after a patient’s disease becomes refractory to this medicine and other current standard drugs. Research does not determine whether an individual will respond similarly.

Common questions about Леналидомид-натив (FAQ)

---

Q: Can Леналидомид-натив cause dizziness or blurred vision?

According to the official product information, dizziness and blurred vision are reported as possible side effects when taking Леналидомид-натив. The official product information advises that patients experiencing these effects should follow their doctor's guidance regarding activities that require attention, such as driving or operating machinery. This is important for patient safety while on the medication.

---

Q: How should Леналидомид-натив be stored?

Regulatory documents state that Леналидомид-натив should be stored in the original blister packaging to protect it from moisture and light. It should be kept at a temperature not exceeding 25°C. As with all medications, keep the medicine out of the sight and reach of children.

---

Q: What is Леналидомид-натив used to treat?

The official product information indicates that Леналидомид-натив is authorized to treat specific types of myeloma and myelodysplastic syndromes (MDS). It is also used in some cases to treat mantle cell lymphoma (MCL). The specific use depends on the type and stage of the disease, and whether it is used alone or combined with other therapies.

---

Q: What should I do if I miss a dose of Леналидомид-натив?

The official product instructions contain specific timing guidance for how to handle a missed dose. If a dose is missed, patients are advised to consult the 'How to use' section of the leaflet or their prescribing physician for the exact steps to follow, ensuring they do not double the dose.

---

Q: Does Леналидомид-натив need to be taken with food?

According to the regulatory documents, Леналидомид-натив can be taken with or without food, providing flexibility for administration. The capsule should always be swallowed whole with water; patients must not open, break, or chew the capsules.

---

Q: Can Леналидомид-натив affect the liver?

Official information indicates that Леналидомид-натив may cause liver problems in some patients, including increases in certain liver enzymes. Due to this potential, monitoring of liver function, typically through blood tests, is a common practice during treatment, as described in the official product information.

---

Q: Is Леналидомид-натив safe for patients with kidney problems?

Studies and official information indicate that patients with reduced kidney function may require a dose or treatment adjustment. This is because the kidneys play a role in clearing the medicine from the body. For these patients, treatment requires specific management and monitoring, as outlined in the official product documents.

Storage and Disposal of Lenalidomide-Nativ

Lenalidomide capsules must be stored at controlled room temperature, specifically between 68 F and 77 F (20 C to 25 C). The medicine must be kept in its original container, which should remain tightly closed.

Storage Requirements

The capsules must be protected from excess heat and moisture; therefore, storage in high-humidity areas, such as a bathroom, is prohibited. For safety, the product must be kept strictly out of the reach and sight of children.

Disposal Instructions

Unused or expired Lenalidomide capsules must not be thrown into household trash or flushed down the toilet or sink (wastewater). Disposal must follow specific pharmaceutical waste procedures. Unused product must be returned to a pharmacy or an approved collection center for disposal in accordance with local regulatory requirements.